US approves Gilead's twice-yearly injection to prevent HIV / Photo: JUSTIN SULLIVAN - GETTY IMAGES NORTH AMERICA/AFP
-
Netflix to buy Warner Bros. in deal of the decade
-
US sanctions equate us with drug traffickers: ICC dep. prosecutor
-
Migration and crime fears loom over Chile's presidential runoff
-
French officer charged after police fracture woman's skull
-
Fresh data show US consumers still strained by inflation
-
Eurovision reels from boycotts over Israel
-
Trump takes centre stage as 2026 World Cup draw takes place
-
Trump all smiles as he wins FIFA's new peace prize
-
US panel votes to end recommending all newborns receive hepatitis B vaccine
-
Title favourite Norris reflects on 'positive' Abu Dhabi practice
-
Stocks consolidate as US inflation worries undermine Fed rate hopes
-
Volcanic eruptions may have brought Black Death to Europe
-
Arsenal the ultimate test for in-form Villa, says Emery
-
Emotions high, hope alive after Nigerian school abduction
-
Another original Hermes Birkin bag sells for $2.86 mn
-
11 million flock to Notre-Dame in year since rising from devastating fire
-
Gymnast Nemour lifts lid on 'humiliation, tears' on way to Olympic gold
-
Lebanon president says country does not want war with Israel
-
France takes anti-drone measures after flight over nuclear sub base
-
Signing up to DR Congo peace is one thing, delivery another
-
'Amazing' figurines find in Egyptian tomb solves mystery
-
Palestinians say Israeli army killed man in occupied West Bank
-
McLaren will make 'practical' call on team orders in Abu Dhabi, says boss Brown
-
Stocks rise as investors look to more Fed rate cuts
-
Norris completes Abu Dhabi practice 'double top' to boost title bid
-
Chiba leads Liu at skating's Grand Prix Final
-
Meta partners with news outlets to expand AI content
-
Mainoo 'being ruined' at Man Utd: Scholes
-
Guardiola says broadcasters owe him wine after nine-goal thriller
-
Netflix to buy Warner Bros. Discovery in deal of the decade
-
French stars Moefana and Atonio return for Champions Cup
-
Penguins queue in Paris zoo for their bird flu jabs
-
Netflix to buy Warner Bros. Discovery for nearly $83 billion
-
Sri Lanka issues fresh landslide warnings as toll nears 500
-
Root says England still 'well and truly' in second Ashes Test
-
Chelsea's Maresca says rotation unavoidable
-
Italian president urges Olympic truce at Milan-Cortina torch ceremony
-
Norris edges Verstappen in opening practice for season-ending Abu Dhabi GP
-
Australia race clear of England to seize control of second Ashes Test
-
Stocks, dollar rise before key US inflation data
-
Trump strategy shifts from global role and vows 'resistance' in Europe
-
Turkey orders arrest of 29 footballers in betting scandal
-
EU hits X with 120-mn-euro fine, risking Trump ire
-
Arsenal's Merino has earned striking role: Arteta
-
Putin offers India 'uninterrupted' oil in summit talks with Modi
-
New Trump strategy vows shift from global role to regional
-
World Athletics ditches long jump take-off zone reform
-
French town offers 1,000-euro birth bonuses to save local clinic
-
After wins abroad, Syria leader must gain trust at home
-
Slot spots 'positive' signs at struggling Liverpool
NYSE - LSE
| RBGPF | 0% | 78.35 | $ | |
| RYCEF | -0.96% | 14.51 | $ | |
| CMSC | -0.25% | 23.422 | $ | |
| BTI | -1.49% | 57.19 | $ | |
| GSK | -0.52% | 48.32 | $ | |
| BP | -3.03% | 36.135 | $ | |
| RIO | -0.9% | 73.07 | $ | |
| VOD | -1.19% | 12.484 | $ | |
| RELX | -0.32% | 40.41 | $ | |
| NGG | -0.58% | 75.475 | $ | |
| CMSD | -0.47% | 23.21 | $ | |
| AZN | 0.29% | 90.295 | $ | |
| SCS | -0.34% | 16.175 | $ | |
| BCC | -0.44% | 73.933 | $ | |
| JRI | 0.22% | 13.78 | $ | |
| BCE | 1.14% | 23.487 | $ |
US approves Gilead's twice-yearly injection to prevent HIV
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV, a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.
Drugs to prevent HIV transmission, known as pre-exposure prophylaxis or PrEP, have existed for more than a decade. But because they typically require taking a daily pill, they have struggled to make a significant dent in global infections.
"This is a historic day in the decades-long fight against HIV," said Daniel O'Day, Gilead's chairman and chief executive officer, in a statement.
Lenacapavir, marketed under the brand name Yeztugo, has been shown in clinical trials to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents -- making it functionally akin to a powerful vaccine.
But optimism may be tempered by the drug's expected eye-watering price tag.
While the company has not disclosed specifics, analysts estimate the US launch price could be as high as $25,000 per year.
Activists are calling for the price to be slashed to $25 per person annually to help end the HIV pandemic.
The approval also comes as President Donald Trump's administration has slashed funding for HIV treatment and prevention programs both overseas and within the United States.
A.Moore--AT
